Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Wendling

Showing results (381-390 of 496) with videos related to

Pageof 50
Sort By:
Clinical Epigenetics|July 13, 2013
Resveratrol, a sirtuin 1 activator, increases IL-6 production by peripheral blood mononuclear cells of patients with knee osteoarthritisDaniel Wendling, Wasim Abbas, Marie Godfrin-Valnet, et al.
RMD Open|March 15, 2023
Factors associated with the retention of secukinumab in patients with axial spondyloarthritis in real-world practice: results from a retrospective study (FORSYA)Maxime Dougados, Julien Lucas, Emilie Desfleurs, et al.
The Journal of Rheumatology|October 3, 2009
Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case seriesEric Toussirot, Jean Marie Berthelot, Edouard Pertuiset, et al.
Annals of the Rheumatic Diseases|February 29, 2024
Sacroiliac radiographic progression over 10 years in axSpA: data from the DESIR inception cohortAnna Molto, Clementina López-Medina, Alexandre Sepriano, et al.
Rheumatology (Oxford, England)|November 24, 2020
Visceral adiposity in patients with psoriatic arthritis and psoriasis alone and its relationship with metabolic and cardiovascular riskEric Toussirot, François Aubin, Maxime Desmarets, et al.
Human Vaccines & Immunotherapeutics|September 20, 2018
Treatment of active rheumatoid arthritis: comparison of patients younger vs older than 75 years (CORPUS cohort)Sachiyo Oishi, Daniel Wendling, Jean Sibilia, et al.
RMD Open|March 1, 2024
Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA studyMaxime Dougados, Audrey Lardy-Cléaud, Emilie Desfleurs, et al.
Joint Bone Spine|March 21, 2026
Serum biomarkers fail to predict response to adalimumab in axial spondyloarthritis: results from discovery and validation cohortsAthan Baillet, Minh Vu Chuong Nguyen, Anaïs Courtier, et al.
EULAR Rheumatology Open|June 29, 2026
Spondyloarthritis and inflammatory bowel disease: towards a more severe and refractory disease phenotypeJuliane Michel, Clément Prati, Lucine Vuitton, et al.
RMD Open|May 13, 2020
5-year follow-up of spinal and sacroiliac MRI abnormalities in early axial spondyloarthritis: data from the DESIR cohortQueeny Madari, Alexandre Sepriano, Sofia Ramiro, et al.
Pageof 50

Showing results (381-390 of 496) with videos related to

Sort By:
Pageof 50
Clinical Epigenetics|July 13, 2013
Resveratrol, a sirtuin 1 activator, increases IL-6 production by peripheral blood mononuclear cells of patients with knee osteoarthritisDaniel Wendling, Wasim Abbas, Marie Godfrin-Valnet, et al.
RMD Open|March 15, 2023
Factors associated with the retention of secukinumab in patients with axial spondyloarthritis in real-world practice: results from a retrospective study (FORSYA)Maxime Dougados, Julien Lucas, Emilie Desfleurs, et al.
The Journal of Rheumatology|October 3, 2009
Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case seriesEric Toussirot, Jean Marie Berthelot, Edouard Pertuiset, et al.
Annals of the Rheumatic Diseases|February 29, 2024
Sacroiliac radiographic progression over 10 years in axSpA: data from the DESIR inception cohortAnna Molto, Clementina López-Medina, Alexandre Sepriano, et al.
Rheumatology (Oxford, England)|November 24, 2020
Visceral adiposity in patients with psoriatic arthritis and psoriasis alone and its relationship with metabolic and cardiovascular riskEric Toussirot, François Aubin, Maxime Desmarets, et al.
Human Vaccines & Immunotherapeutics|September 20, 2018
Treatment of active rheumatoid arthritis: comparison of patients younger vs older than 75 years (CORPUS cohort)Sachiyo Oishi, Daniel Wendling, Jean Sibilia, et al.
RMD Open|March 1, 2024
Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA studyMaxime Dougados, Audrey Lardy-Cléaud, Emilie Desfleurs, et al.
Joint Bone Spine|March 21, 2026
Serum biomarkers fail to predict response to adalimumab in axial spondyloarthritis: results from discovery and validation cohortsAthan Baillet, Minh Vu Chuong Nguyen, Anaïs Courtier, et al.
EULAR Rheumatology Open|June 29, 2026
Spondyloarthritis and inflammatory bowel disease: towards a more severe and refractory disease phenotypeJuliane Michel, Clément Prati, Lucine Vuitton, et al.
RMD Open|May 13, 2020
5-year follow-up of spinal and sacroiliac MRI abnormalities in early axial spondyloarthritis: data from the DESIR cohortQueeny Madari, Alexandre Sepriano, Sofia Ramiro, et al.
Pageof 50